Global & Regional Health Technology Assessment最新文献

筛选
英文 中文
Valutazione dei tempi di accesso per le nuove entità chimiche in Italia: un’analisi critica del periodo 2018-2024. 意大利新化学实体进入时间的评估:对2018-2024年期间的关键分析。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-05-16 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3422
Alessandro Tedesco, Marzia Bonfanti, Asia Barugolo, Fulvio Luccini, Patrizia Berto
{"title":"Valutazione dei tempi di accesso per le nuove entità chimiche in Italia: un’analisi critica del periodo 2018-2024.","authors":"Alessandro Tedesco, Marzia Bonfanti, Asia Barugolo, Fulvio Luccini, Patrizia Berto","doi":"10.33393/grhta.2025.3422","DOIUrl":"10.33393/grhta.2025.3422","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"141-150"},"PeriodicalIF":0.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data. 免疫球蛋白A肾病患者的保健通过意大利行政数据的回顾性观察研究。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3397
Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini
{"title":"Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.","authors":"Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini","doi":"10.33393/grhta.2025.3397","DOIUrl":"https://doi.org/10.33393/grhta.2025.3397","url":null,"abstract":"<p><strong>Background: </strong>Immunoglobulin A nephropathy (IgAN) is a rare disease poorly described in real-world settings. This observational retrospective study aimed to assess the direct healthcare burden of new IgAN patients on the Italian National Healthcare Service (SSN).</p><p><strong>Methods: </strong>From the Fondazione Ricerca e Salute's database (administrative healthcare data of ~5.5 million inhabitants/year), inpatients with new potential in-hospital biopsy-verified IgAN from 2016 to 2019 were identified. Dispensations of IgAN-recommended and other drugs, kidney replacement therapies (KRT), hospital and emergency department (ED) admissions, local outpatient specialist care, and related direct costs were assessed throughout a 3-year follow-up.</p><p><strong>Results: </strong>New IgAN patients (n = 292) were identified (incidence/year: 1.25/100 000 inhabitants); 64% of patients were male; the median age was 41 (27; 57) years. Annual consumption of most healthcare resources decreased from Year 1 to 3: from 90% to 84% of patients received ≥1 IgAN-recommended drug; from 100% (due to selection criteria) to 15% of patients underwent overnight hospitalizations; from 8% to 3% patients underwent day hospitalizations; from 31% to 21% patients underwent ≥1 ED access; from 87% to 85% patients received local outpatient specialist services. Of all patients, 2-4% were treated with KRT, and ~91% received other drugs. The per capita mean total annual cost was €7441 in Year 1 (hospitalizations accounting for 73% due to selection criteria), €3497 in Year 2, and €3243 in Year 3 (drugs accounting for 51%, mostly attributable to other drugs).</p><p><strong>Conclusion: </strong>This real-world study shows a substantial direct healthcare burden for new IgAN patients arising from IgAN-specific care and comorbidities.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"130-140"},"PeriodicalIF":0.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control. 辛奥巴酸作为治疗局灶性癫痫控制不充分的成人的替代治疗方案的成本效益。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-05-09 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3341
Martina Paoletti, Angela Ragonese, Luca Budassi, Andrea Marcellusi
{"title":"Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control.","authors":"Martina Paoletti, Angela Ragonese, Luca Budassi, Andrea Marcellusi","doi":"10.33393/grhta.2025.3341","DOIUrl":"https://doi.org/10.33393/grhta.2025.3341","url":null,"abstract":"<p><strong>Introduction: </strong>This study assesses the cost-effectiveness of cenobamate relative to brivaracetam, lacosamide, eslicarbazepine acetate, and perampanel in the management of focal onset seizures (FOS). The objective is to determine whether cenobamate offers enhanced therapeutic benefits and economic viability.</p><p><strong>Methods: </strong>A comprehensive cost-effectiveness analysis was performed using a lifetime horizon model that encompassed drug acquisition costs, background therapy, monitoring, and seizure management expenses. The incremental cost-effectiveness ratio (ICER) was calculated to evaluate the quality-adjusted life years (QALYs) gained from cenobamate compared to its alternatives.</p><p><strong>Results: </strong>Findings revealed that cenobamate while incurring slightly higher initial acquisition costs, leads to significant cost offsets due to reductions in overall seizure management expenses and minimized reliance on subsequent anti-seizure medications (ASMs). Additionally, cenobamate significantly enhances patient quality of life, demonstrated by superior response rates (seizure reduction >50%) and remission rates (100% seizure reduction) compared to the analyzed comparators. The cost-effectiveness analysis established that cenobamate is dominant across all evaluated treatment options, achieving greater QALYs at a lower total cost.</p><p><strong>Conclusion: </strong>Cenobamate represents a more effective and economically advantageous treatment for patients with FOS when compared to brivaracetam, lacosamide, eslicarbazepine acetate, and perampanel. Its capacity to improve seizure control and enhance the quality of life, alongside favorable economic implications, underscores its position as the preferred therapeutic option in this patient population.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"118-129"},"PeriodicalIF":0.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analisi di costo-efficacia di Brentuximab Vedotin + CHP in pazienti con linfoma anaplastico a grandi cellule sistemico. Brentuximab Vedotin + CHP的成本效益分析,用于全身大细胞anapltif患者。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3306
Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli
{"title":"Analisi di costo-efficacia di Brentuximab Vedotin + CHP in pazienti con linfoma anaplastico a grandi cellule sistemico.","authors":"Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli","doi":"10.33393/grhta.2025.3306","DOIUrl":"https://doi.org/10.33393/grhta.2025.3306","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"106-117"},"PeriodicalIF":0.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gli strumenti regionali di governo del comportamento prescrittivo e della spesa farmaceutica: dalla letteratura alle esperienze concrete e raccomandazioni di un panel di esperti. 管理处方行为和药物支出的区域工具:从文献到专家小组的实际经验和建议。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-04-24 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3324
Giovanna Scroccaro, Luca Piccoli, Giacomo Vitturi, Maria Cristina Carena, Gianfranco Valenzano
{"title":"Gli strumenti regionali di governo del comportamento prescrittivo e della spesa farmaceutica: dalla letteratura alle esperienze concrete e raccomandazioni di un panel di esperti.","authors":"Giovanna Scroccaro, Luca Piccoli, Giacomo Vitturi, Maria Cristina Carena, Gianfranco Valenzano","doi":"10.33393/grhta.2025.3324","DOIUrl":"https://doi.org/10.33393/grhta.2025.3324","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"98-105"},"PeriodicalIF":0.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gestione e utilizzo del Fondo Farmaci Innovativi: un’indagine qualitativa multistakeholder sulle pratiche regionali e locali. 创新药物基金的管理和使用:对区域和地方做法进行多利益相关者定性调查。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-03-27 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3433
Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, Andrea Marcellusi
{"title":"Gestione e utilizzo del Fondo Farmaci Innovativi: un’indagine qualitativa <i>multistakeholder</i> sulle pratiche regionali e locali.","authors":"Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, Andrea Marcellusi","doi":"10.33393/grhta.2025.3433","DOIUrl":"10.33393/grhta.2025.3433","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"89-97"},"PeriodicalIF":0.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL). 评估Waldenström大球蛋白血症(WM)、边缘带淋巴瘤(MZL)和慢性淋巴细胞白血病(CLL)的经济负担。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-03-11 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3365
Matteo Scortichini, Martina Paoletti, Angela Ragonese, Antonio Cuneo, Marco Vignetti, Pier Luigi Zinzani
{"title":"Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL).","authors":"Matteo Scortichini, Martina Paoletti, Angela Ragonese, Antonio Cuneo, Marco Vignetti, Pier Luigi Zinzani","doi":"10.33393/grhta.2025.3365","DOIUrl":"10.33393/grhta.2025.3365","url":null,"abstract":"<p><strong>Introduction: </strong>In Italy, Non-Hodgkin Lymphomas (NHL), including Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL), are among the most common hematologic cancers. These conditions mainly affect the elderly, who often have multiple comorbidities, complicating management and imposing significant burdens on patient quality of life and healthcare systems.</p><p><strong>Objective: </strong>This study aimed to estimate the economic burden of selected B-cell lymphomas in Italy, providing insights for decision-makers to improve patient management and resource allocation.</p><p><strong>Method: </strong>Data from the Italian Hospital Discharges Records (SDO) and the National Institute for Social Security were analyzed to estimate direct healthcare costs and social security costs from 2016 to 2019.</p><p><strong>Results: </strong>A total of 93,712 hospital discharges were recorded, with MZL being the most common diagnosis, followed by CLL and WM. Most patients were male, and the 70-79 age group was most prevalent. MZL had the highest costs, followed by CLL and WM. Adverse events notably increased total expenditures, with variations across different pathologies. Direct healthcare costs totaled 533.6 million euros, while social security costs amounted to 240.9 million euros.</p><p><strong>Conclusion: </strong>This study highlights the significant economic burden of selected B-cell lymphomas in Italy. Effective management strategies are crucial for reducing costs and optimizing resource allocation in the healthcare system.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"80-88"},"PeriodicalIF":0.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia. 在意大利治疗中,upadacitinib 30 mg和dupilumab 300 mg用于治疗中度重度阿特皮炎患者的费用。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-03-10 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3458
Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi
{"title":"Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia.","authors":"Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi","doi":"10.33393/grhta.2025.3458","DOIUrl":"10.33393/grhta.2025.3458","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"70-79"},"PeriodicalIF":0.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine. D.I.Ri.M.O。项目:医院医学处方的撤销、不适宜性评价及治疗调解。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-03-03 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3194
Maria Giulia Pollice, Luca Degli Esposti, Cataldo Procacci, Salvatore Lenti, Domenica Ancona, Carmela Nappi, Biagio Lacolare, Anna Maria Tesse, Domenico Leuci, Mara Masullo, Domenico Tricarico
{"title":"D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine.","authors":"Maria Giulia Pollice, Luca Degli Esposti, Cataldo Procacci, Salvatore Lenti, Domenica Ancona, Carmela Nappi, Biagio Lacolare, Anna Maria Tesse, Domenico Leuci, Mara Masullo, Domenico Tricarico","doi":"10.33393/grhta.2025.3194","DOIUrl":"10.33393/grhta.2025.3194","url":null,"abstract":"<p><strong>Background: </strong>In the Italian healthcare landscape, the management of chronic pathologies is a priority. Often, the elderly patient suffers from several pathologies at once and is commonly on polytherapy: this can easily bring potentially harmful errors in drug therapy. The D.I.Ri.M.O. project took place in an Internal Medicine department and aimed to reduce medication errors and improve the state of health through the Pharmacological Reconciliation procedure.</p><p><strong>Methods: </strong>From June to October 2022, the team archived therapies for 70 hospitalized patients aged over 65 years and suffering from two or more chronic diseases. For each patient enrolled, the team developed a reconciliation board; afterward, the physician and the pharmacist proceeded to remodulate therapies, especially in those patients with serious interactions.</p><p><strong>Results: </strong>The team collected 287 drug interactions and then classified them according to the Intercheck Web software classification: 36 class D (very serious), 49 class C (major), 174 class B (moderate), and 28 class A (minor). The modified therapies at discharge were 77.14%. This restriction brought about the removal of unnecessary drugs. After six months, the team observed an improvement in the health conditions of the patients enrolled.</p><p><strong>Conclusions: </strong>By increasing the patient's awareness and reducing the number of potentially inappropriate prescriptions, it is possible to improve the effectiveness of therapies. It is also possible to look at a saving policy to make the economic resources better allocated.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"61-69"},"PeriodicalIF":0.4,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ottimizzazione nel trattamento del soggetto con HIV: analisi di impatto economico e organizzativo di Bictegravir/Emtricitabina/Tenofovir Alafenamide. 艾滋病毒治疗的优化:bicinteavir /Emtricitabina/Tenofovir Alafenamide的经济和组织影响分析。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.33393/grhta.2025.3292
Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini, Emanuela Foglia
{"title":"Ottimizzazione nel trattamento del soggetto con HIV: analisi di impatto economico e organizzativo di Bictegravir/Emtricitabina/Tenofovir Alafenamide.","authors":"Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini, Emanuela Foglia","doi":"10.33393/grhta.2025.3292","DOIUrl":"https://doi.org/10.33393/grhta.2025.3292","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"49-60"},"PeriodicalIF":0.4,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信